Compare ARK Genomic Revolution ETF (ARKG) vs ConocoPhillips (COP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs ConocoPhillips — how do they compare? ARK Genomic Revolution ETF trades at $40.88, while ConocoPhillips trades at $112.14 (market cap $132.84B). The key difference: ConocoPhillips pays a 3.08% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, ConocoPhillips nearer its low. Which is the better fit depends on your goals.
| ARKG | COP | |
|---|---|---|
Sector | Sector/Thematic | Energy |
52-Week High | $43.57 | $133.80 |
52-Week Low | $23.09 | $85.66 |
Market Cap | — | $132.84B |
Enterprise Value | — | $149.81B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
ConocoPhillips (COP) trades at $109.04, up 0.94% with a bullish technical signal despite mixed moving averages. The company maintains solid fundamentals with $58.94B revenue, 12.58% net margin, and consistent cash flow generation. Recent earnings show beats in Q3 2025 and Q1 2026, while analysts project strong Q2 2026 EPS of $2.85. The stock offers a dividend yield with recent $0.84 payout, supported by 74.51% buy ratings from coverage analysts.
COP presents a compelling value opportunity with P/E of 18.48 and EV/EBITDA of 6.08 below sector averages. The consensus price target of $137.14 implies 26% upside potential. Key risks include oil price volatility, geopolitical tensions affecting Middle East supply, and declining profit margins from 23.79% in 2022 to 13.55% in 2025. The upcoming Q2 earnings on August 6, 2026, will be crucial for validating growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →
